Teva Pharmaceuticals (Czechia)

Recent papers from Teva Pharmaceuticals (Czechia)

1. Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteersHeadache The Journal of Head and Face Pain · 2026
2. Factors associated with rates of long-acting injectable antipsychotic use for schizophrenia: A subgroup analysis of the multinational ADVANCE studyPsychiatry Research · 2026
3. Development of Extended-Release Oral Dosage Forms of Salbutamol Sulfate Using the Hot-Melt Extrusion Manufacturing TechniqueDrug Development and Industrial Pharmacy · 2026
4. Real-world treatment patterns and outcomes of deutetrabenazine in patients with chorea associated with Huntington disease: A retrospective chart review studyJournal of Huntington s Disease · 2026
5. Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extensionCephalalgia · 2026
6. Medicinal Chemistry Perspectives on PFAS in Drug Design: Fluorinated Motifs, Innovation, and Patient ImpactJournal of Medicinal Chemistry · 2026
7. Cyclosporin (0.09%) Ophthalmic Solution for the Treatment of Dry Eye Disease – A Narrative ReviewCurrent Eye Research · 2026
8. Strategic lean practices for Industry 5.0 manufacturingInternational Journal of Production Research · 2026
9. Comparison of pharmacokinetics of sitagliptin 100 mg tablets in healthy Asian Indian and Thai volunteersIndian Journal of Pharmacology · 2026
10. Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use (P7-16.003)Neurology · 2026
11. Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy ParticipantsClinical Drug Investigation · 2026
12. Impact of Early Fremanezumab Initiation and Treatment Pauses on the Reduction of Monthly Migraine Days: Analyses from the PEARL Study (P10-15.007)Neurology · 2026
13. Treatment with Fremanezumab Attenuates the Association Between Weather and Headache in Participants with Episodic Migraine: A Post Hoc Analysis of the HALO-EM and HALO-LTS Studies (P10-15.004)Neurology · 2026
14. Linking Degradation Pathways, Additive Transformation, and Contaminant Profiles in Post-Consumer HDPE: Implications for Recycling QualityPolymers · 2026
15. Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.Journal of Clinical Oncology · 2026
16. CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.Journal of Clinical Oncology · 2026
17. Real-world patient characteristics, treatment patterns, and healthcare resource utilization and costs of tardive dyskinesia in GermanyJournal of Psychiatric Research · 2026
18. Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to HarmNeuropsychiatric Disease and Treatment · 2026
19. Impact of Healthcare Professional Role and Care Setting on Attitudes Toward Long-Acting Injectable Antipsychotics for Schizophrenia: A Subgroup Analysis of the Multinational ADVANCE StudySchizophrenia Bulletin Open · 2026
20. Value, development challenges, and strategies for gaining internal endorsement of digitally connected subcutaneous drug delivery devices: a survey of pharmaceutical stakeholdersFrontiers in Digital Health · 2026